In a recent statement, Plandai Biotechnology Inc (OTCMKTS:PLPL) announced that its flagship product Phytofare has been adapted by USN (United Sports Nutrition) to develop a new range of products. As per the reports, these products are been developed to address the needs of customers based in New Zealand and Australia.
Phytofare is Plandai’s green tea catechin-based product that delivers active ingredients to blood. The important thing about these ingredients is that they remain in blood for more time than the normal generic supplements.
It’s not the first time when both the companies have entered into any agreement. Earlier, they signed an agreement under which USN has to use Phytofare in all the green tea based products developed and sold in South Africa and Europe. As the competition in the market is on the rise; therefore, both the companies want to make sure that their commercial relation can provide them aid in the future.
As part of the renewed deal, USN will look forward to using its portfolio of all the manufacturers in New Zealand and Australia for expanding Phytofare’s reach. Management teams of USN and Plandai hope that this step will help them touch newer growth level in these two markets.
Meanwhile, Metabolix, Inc. (NASDAQ:MBLX) has announced the launch of Yield10 Bioscience with an objective of development and commercialization of various innovative projects in crop science. A recent report of Food and Agricultural Organization, USA cited that the global population will increase to 9 billion by 2050; hence, there will be an additional need for food production. The launch of Yield10 Bioscience will help Metabolix taking its efforts to the next level in this direction.
Herborium Group, Inc. (OTCMKTS:HBRM) has floated multiple websites equipped with cutting-edge technology for the promotion and marketing of its flagship product named AcnEase. It is used to treat health issues like acne and rosacea through natural ways.